Text Size

Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor

This study is currently recruiting participants.
Verified December 2011 by King Faisal Specialist Hospital & Research Center
Sponsor:
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT00531583
First received: September 17, 2007
Last updated: December 11, 2011
Last verified: December 2011
History of Changes
  Purpose

Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation program for pts w/AML in 1st & 2nd complete remission w/no HLA matched related donor


Condition Intervention
Leukemia, Monocytic, Acute
 Drug: Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor

Resource links provided by NLM:

MedlinePlus related topics: Leukemia
U.S. FDA Resources

Further study details as provided by King Faisal Specialist Hospital & Research Center:

Primary Outcome Measures:
  • Efficacy [ Time Frame: 2009-2015 ] [ Designated as safety issue: No ]

Estimated Enrollment: 350
Study Start Date: March 2001
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation
    Autologous PBSCT
  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with AML in 1st & 2nd complete remission w/no HLA matched related donor
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00531583

Contacts
Contact: Fahad AlMohareb, MD fmohareb@kfshrc.edu.sa

Locations
Saudi Arabia
KFSH&RC Recruiting
Riyadh, Saudi Arabia, 1211
Contact: Fahad AlMohareb, MD            
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: Fahad AlMohareb KFSH&RC
  More Information

No publications provided

Responsible Party: King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT00531583     History of Changes
Other Study ID Numbers: RAC#2001-004
Study First Received: September 17, 2007
Last Updated: December 11, 2011
Health Authority: ORA: KFSH&RC, Riyadh, Saudi Arabia

Keywords provided by King Faisal Specialist Hospital & Research Center:
AML in 1st & 2nd complete remission w/no HLA matched related donor

Additional relevant MeSH terms:
Leukemia
Leukemia, Monocytic, Acute
Neoplasms by Histologic Type
 Neoplasms
Leukemia, Myeloid, Acute
Leukemia, Myeloid

ClinicalTrials.gov processed this record on May 16, 2013